How does abaloparatide compare to teriparatide?

Both are anabolic bone-building peptides with the same 2-year treatment limit. Abaloparatide may produce faster early BMD increases and has lower hypercalcemia incidence (3% vs 6%). Head-to-head fracture data is limited. Choice depends on cost, insurance, and patient factors.

Can abaloparatide and teriparatide be used sequentially?

No. The FDA black box warning applies to both drugs collectively: lifetime cumulative exposure to PTH analogs must not exceed 2 years. Using them sequentially would exceed this limit. After 2 years, transition to an antiresorptive agent.

Treatment hubFDA ApprovedDeep Dive

Abaloparatide Treatment Guide: Tymlos, Cost and Provider Paths

In the United States, Abaloparatide is an FDA-approved peptide therapy. Osteoporosis in postmenopausal women at high risk of fracture

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.

Last reviewed: April 27, 2026

Overview

Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP 1-34) approved by the FDA for osteoporosis in postmenopausal women at high risk of fracture. Like teriparatide, it is an anabolic bone-building agent with a more transient receptor activation profile.

Approved Product Paths

Tymlos

Branded abaloparatide pathway. Osteoporosis in postmenopausal women at high risk of fracture

Benefits

•Anabolic bone-building agent for severe osteoporosis
•Significant reduction in vertebral and non-vertebral fractures
•Faster early BMD gains than teriparatide in some studies
•Lower incidence of hypercalcemia vs teriparatide

Side Effects & Friction

•Hypercalcemia (less frequent than teriparatide)
•Dizziness, nausea, headache
•Palpitations and orthostatic hypotension
•Injection site reactions

Administration Routes

Subcutaneous injection

Cost Reality

Abaloparatide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in healing & recovery who can evaluate whether Abaloparatide fits the patient's clinical profile and insurance constraints.

How Abaloparatide Works

Abaloparatide is a synthetic 34-amino-acid analog of parathyroid hormone-related protein (PTHrP). Like teriparatide, it is an anabolic osteoporosis therapy that stimulates bone formation, but with potentially faster onset and less bone resorption stimulation.

Abaloparatide is a PTHrP analog that binds to the PTH1 receptor on osteoblasts, activating the same anabolic signaling pathways as teriparatide. However, its binding kinetics differ, producing a more transient receptor activation.

The transient activation pattern may explain abaloparatide's more favorable balance of bone formation vs resorption. In preclinical models and clinical trials, abaloparatide produced greater early BMD gains than teriparatide with similar or lower markers of bone resorption.

Abaloparatide increases bone formation markers (P1NP) more rapidly than teriparatide in the first 6 months. BMD gains at the spine are comparable or slightly greater than teriparatide.

Like teriparatide, abaloparatide is limited to 2 years of cumulative lifetime use due to the theoretical osteosarcoma risk observed in rodent studies.

After completing abaloparatide therapy, patients should transition to an antiresorptive agent (bisphosphonate or denosumab) to preserve bone gains.

Abaloparatide is administered as a daily subcutaneous injection. The pen device delivers 80 mcg per dose.

PTH/PTHrP receptor (PTH1R)OsteoblastsOsteocytes

Clinical Trial Evidence

ACTIVE trial

Population: Postmenopausal women with osteoporosis

N= 2,463

Duration: 18 months

Endpoint: New vertebral fractures

86% reduction in vertebral fractures vs placebo (p<0.001)
43% reduction in non-vertebral fractures (p=0.049)
Spine BMD increased 9.2% vs 5.5% teriparatide and 0.6% placebo
Hip BMD increased 3.4% vs 2.0% teriparatide

ACTIVITY extension

PMID: 29731295

Population: Patients completing ACTIVE trial

N= 1,139

Duration: 24 months total

Endpoint: Sustained efficacy and safety

BMD gains sustained at 24 months
Fracture reduction benefit maintained
No new safety signals

Dosing & Administration

Postmenopausal osteoporosis at high fracture risk (Tymlos)Subcutaneous · Once daily

Starting: 80 mcg once daily

Titration: No titration; fixed dose

Maintenance: 80 mcg once daily

Maximum: 80 mcg once daily

•Inject subcutaneously into abdomen
•Take at same time each day
•Patient should sit or lie down if dizziness occurs
•Store in refrigerator; do not freeze or use if frozen
•Pen delivers 30 doses; discard after 30 days

Side Effect Profile

Common

Hypercalciuriamild18%

Increased urinary calcium; usually asymptomatic

Dizzinessmild10%

Orthostatic; usually transient

Nauseamild8%

Transient

Headachemild8%

Mild

Palpitationsmild5%

Usually benign; monitor if persistent

Serious

Osteosarcoma (theoretical)severeNot observed in humans

Rodent finding at supraphysiologic doses; 2-year treatment limit

Hypercalcemiamoderate3%

Usually mild and transient

Orthostatic hypotensionmoderate3%

May cause dizziness and falls

Contraindications & Warnings

Do Not Use

Paget disease of bone
Prior radiation therapy involving skeleton
Bone metastases or skeletal malignancies
Hypercalcemia
Pregnancy or breastfeeding
Patients at increased baseline risk for osteosarcoma

Important Warnings

Boxed warning for osteosarcoma risk based on rat studies at supraphysiologic doses. No confirmed human cases. 2-year cumulative lifetime limit.
Orthostatic hypotension: may cause dizziness upon standing, especially after first doses. Advise patients to sit or lie down if symptomatic.
Hypercalcemia: monitor serum calcium if symptoms suggestive.
Urolithiasis risk may increase due to hypercalciuria.
Must follow with antiresorptive therapy after discontinuation.

Drug Interactions

Drug	Interaction	Severity	Mechanism
Bisphosphonates	Should not be combined simultaneously	major	Sequence anabolic first, then antiresorptive
Denosumab	Should not be combined simultaneously	major	Same rationale as bisphosphonates
Digitalis	Hypercalcemia increases toxicity risk	moderate	Monitor calcium if on digitalis
Calcium supplements	May increase hypercalcemia risk	minor	Additive calcium load

Monitoring Requirements

Serum calcium at 1 month, 3 months, and every 6 months
DXA BMD at 12 and 18-24 months
Urine calcium if urolithiasis history
Bone turnover markers (P1NP, CTX) optional
Blood pressure and orthostatic symptoms
Transition plan to antiresorptive before month 24

How Abaloparatide Compares

BMD increaseAbaloparatide advantage

Abaloparatide: Spine +9.2% at 18 months

Teriparatide (Forteo): Spine +7.2% at 18 months

Abaloparatide may produce slightly greater BMD gains

Fracture reductionTeriparatide advantage

Abaloparatide: 86% vertebral, 43% non-vertebral

Teriparatide: 65% vertebral, 53% non-vertebral

Comparable fracture protection; different trial designs

Bone resorptionAbaloparatide advantage

Abaloparatide: Lower CTX increase

Teriparatide: Higher resorption markers

Abaloparatide may have more favorable formation/resorption balance

Orthostatic hypotensionTeriparatide advantage

Abaloparatide: Higher incidence (3-5%)

Teriparatide: Lower incidence

Abaloparatide causes more dizziness/orthostasis

MechanismRomosozumab (Evenity) advantage

Abaloparatide: PTH1R agonist

Romosozumab (Evenity): Sclerostin antibody

Romosozumab may act faster but has CV safety questions

BMD increaseAbaloparatide advantage

Abaloparatide: Spine +9.2%

Alendronate: Spine +5-8%

Anabolic agents outperform bisphosphonates for severe osteoporosis

Evidence Quality Assessment

Overall Evidence Grade: A

A = Strong evidence from multiple large RCTs

Human RCTs: Extensive: ACTIVE trial (n=2,463) with fracture endpoints

Long-term data: Moderate: 24-month extension data; 2-year limit means no longer data

Real-world evidence: Growing: Post-marketing data since 2017

Regulatory status: FDA-approved for postmenopausal osteoporosis at high fracture risk

Is Abaloparatide Right for You?

Ideal Candidates

Postmenopausal women with severe osteoporosis (T-score ≤-3.0) or prior fragility fracture
Patients who failed or cannot tolerate bisphosphonates
Those seeking maximum BMD gain in shortest time
Patients who may benefit from greater formation/resorption balance

Avoid

Paget disease
Prior skeletal radiation
Active malignancy or bone metastases
Hypercalcemia
Patients with history of significant orthostatic hypotension or fall risk

Use With Caution

History of urolithiasis
Mild renal impairment
Patients on antihypertensives (orthostasis risk)
Elderly patients with fall risk

Cost & Insurance Deep Dive

List Price (Monthly)

~$3,500-$4,000/month

Cash-Pay Range

$3,000-$4,000/month

Insurance Coverage Rate

~70-85% with proper documentation

Prior Auth Likelihood

Very high; requires DXA, fracture history, often bisphosphonate failure

Savings Programs

Tymlos patient assistanceFree for eligible patients

Eligibility: Uninsured, income ≤400% FPL

Annual application

Savings cardMay reduce copay significantly

Eligibility: Commercially insured

Not for government insurance

Cost-Effectiveness Notes

•Priced similarly to teriparatide
•ACTIVE trial fracture data supports cost-effectiveness in high-risk patients
•2-year limit caps total drug cost
•Sequential antiresorptive adds cost but is necessary to preserve gains

Ready to find a abaloparatide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a abaloparatide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Abaloparatide FAQ

Sources

1. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
J Clin Endocrinol Metab • 2020
Claim type: clinical
View source →
2. FDA Information on Abaloparatide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.